Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Ammoxetine in Depression
NCT05762458Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Feb 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ammoxetine in major depressive disorder (MDD), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
ammoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05762458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05762458.